MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Search

Sana Biotechnology Inc

Chiusa

SettoreSettore sanitario

5.51 9.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.11

Massimo

5.68

Metriche Chiave

By Trading Economics

Entrata

-44M

-94M

Margine di Profitto

-321.09

Dipendenti

194

EBITDA

-48M

-95M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+64.02% upside

Dividendi

By Dow Jones

Utili prossimi

7 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

376M

1.1B

Apertura precedente

-4.47

Chiusura precedente

5.51

Notizie sul Sentiment di mercato

By Acuity

50%

50%

160 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Sana Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 ott 2025, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 ott 2025, 22:14 UTC

Discorsi di Mercato

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 ott 2025, 22:00 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 ott 2025, 21:49 UTC

Acquisizioni, Fusioni, Takeovers

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 ott 2025, 20:56 UTC

Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 ott 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 ott 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

20 ott 2025, 20:38 UTC

Utili

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 ott 2025, 20:38 UTC

Utili

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 ott 2025, 20:38 UTC

Utili

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 ott 2025, 20:36 UTC

Utili

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 ott 2025, 20:36 UTC

Utili

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 ott 2025, 20:36 UTC

Utili

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 ott 2025, 20:36 UTC

Utili

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 ott 2025, 20:16 UTC

Discorsi di Mercato

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 ott 2025, 20:05 UTC

Utili

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 ott 2025, 19:39 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 ott 2025, 19:34 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 ott 2025, 19:32 UTC

Discorsi di Mercato

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 ott 2025, 19:00 UTC

Acquisizioni, Fusioni, Takeovers

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 ott 2025, 18:29 UTC

Discorsi di Mercato

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 ott 2025, 18:11 UTC

Discorsi di Mercato

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 ott 2025, 18:04 UTC

Discorsi di Mercato

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 ott 2025, 17:03 UTC

Discorsi di Mercato

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 ott 2025, 17:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 ott 2025, 17:01 UTC

Discorsi di Mercato

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 ott 2025, 16:43 UTC

Discorsi di Mercato

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 ott 2025, 16:25 UTC

Discorsi di Mercato

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Confronto tra pari

Modifica del prezzo

Sana Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

64.02% in crescita

Previsioni per 12 mesi

Media 8.25 USD  64.02%

Alto 12 USD

Basso 5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sana Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.68 / 1.87Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

160 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat